Skip to content
value.today

Vitae Pharmaceuticals, Inc

Formerly Vitae Pharmaceuticals Inc, CONCURRENT PHARMACEUTICALS INC

Total raised
$15 M
1 round on record
Latest round
$15 M
Jun 2009
First round on record
Jun 2009
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vitae Pharmaceuticals, Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2009$15 MNo. 1$10 to $50 million

Vitae Pharmaceuticals, Inc: Raise no. 1, Jun 2009

Investors in this round

1 investor had bought by the notice of Jun 10, 2009: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Vitae Pharmaceuticals, Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Hatfield · Executive Officer, Director
  • Richard Gregg · Executive Officer
  • Tina Fiumenero · Executive Officer
  • Bryan Roberts · Director
  • Charles Newhall · Director
  • Donald Hayden · Director
  • James Tananbaum · Director
  • Peter Barrett · Director
  • Robert Gunderson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tina Fiumenero, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 10, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vitae Pharmaceuticals, Inc chose not to state its revenue in its newest notice of a funding round (Jun 2009).

    SEC Form D · Jun 2009

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2009

That is all the official record says: Vitae Pharmaceuticals, Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Vitae Pharmaceuticals, Inc
InvestorKindAmountRoundRoleSource
Nea Partners 10 L.P.Fund or asset managernot statednot statedHeld Series A-2, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
New Enterprise Associates 10 L.P.Fund or asset managernot statednot statedHeld Series A-2, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Prospect Management Co II LLCFund or asset managernot statednot statedHeld Series A-2, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Prospect Management Co LLCFund or asset managernot statednot statedHeld Series A-2, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Vef Management III LLCFund or asset managernot statednot statedHeld Series A-2, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock AssociatesOthernot statednot statedHeld Series A-2, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Associates III LPFund or asset managernot statednot statedHeld Series A-2, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Entrepreneurs Fund III LPFund or asset managernot statednot statedHeld Series A-2, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Management III LLCFund or asset managernot statednot statedHeld Series A-2, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vitae Pharmaceuticals, Inc
NameRoleNamed in
Jeffrey HatfieldExecutive officerJun 2009
Richard GreggExecutive officerJun 2009
Tina FiumeneroExecutive officerJun 2009
Bryan RobertsDirectorJun 2009
Charles NewhallDirectorJun 2009
Donald HaydenDirectorJun 2009
James TananbaumDirectorJun 2009
Jeffrey HatfieldDirectorJun 2009
Peter BarrettDirectorJun 2009
Robert GundersonDirectorJun 2009